【中金：维持康方生物(09926.HK)跑赢行业评级 上调目标价至225.00港元】智通财经APP获悉，中金发布研报称，维持康方生物(09926.HK)2025年和2026年盈利预测不变。维持跑赢行业评级，该行上调AK112临床成功率并将Summit
AK112再授权预期打入估值，根据DCF模型，该行上调目标价87.5%至225.00港币(33.1%上行空间)。公司公布1H25业绩：收入14.12亿元，同比增长37.75%，业绩符合该行预期。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.